{"id":12017,"date":"2021-03-01T16:56:13","date_gmt":"2021-03-01T15:56:13","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=12017"},"modified":"2021-09-08T09:47:13","modified_gmt":"2021-09-08T07:47:13","slug":"inflarx-a-bmt-investee-partner-completed-a-minimum-75-mio-usd-equity-raise-greatly-enhancing-the-companys-ability-to-continue-advancing-its-promising-pipeline-through-multiple-significant-miles","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2021\/inflarx-a-bmt-investee-partner-completed-a-minimum-75-mio-usd-equity-raise-greatly-enhancing-the-companys-ability-to-continue-advancing-its-promising-pipeline-through-multiple-significant-miles\/","title":{"rendered":"InflaRx, a bm|t Investee-Partner, completed a minimum 75 Mio. USD equity raise, greatly enhancing the company\u2019s ability to continue advancing its promising pipeline through multiple significant milestones."},"content":{"rendered":"
InflaRx N.V. (Nas\u00addaq: IFRX), a clin\u00adi\u00adcal-stage bio\u00adphar\u00adma\u00adceu\u00adti\u00adcal com\u00adpany devel\u00adop\u00ading anti-inflam\u00adma\u00adtory ther\u00ada\u00adpeu\u00adtics by tar\u00adget\u00ading the com\u00adple\u00adment sys\u00adtem, announced today that it has com\u00adpleted its under\u00adwrit\u00adten pub\u00adlic offer\u00ading of 15,000,000 com\u00admon shares at a price of $5.00 per share. For each com\u00admon share pur\u00adchased, an investor received a war\u00adrant to pur\u00adchase a com\u00admon share at an exer\u00adcise price of $5.80. The gross pro\u00adceeds to InflaRx from the offer\u00ading were approx\u00adi\u00admately $75 mil\u00adlion, before deduct\u00ading the under\u00adwrit\u00ading dis\u00adcount and other offer\u00ading expenses and exclud\u00ading the exer\u00adcise of any war\u00adrants. The Com\u00adpany intends to use the net pro\u00adceeds from the offer\u00ading pri\u00admar\u00adily to fund research and devel\u00adop\u00adment expenses for its clin\u00adi\u00adcal and pre\u00adclin\u00adi\u00adcal research and devel\u00adop\u00adment activ\u00adi\u00adties and for work\u00ading cap\u00adi\u00adtal and gen\u00aderal cor\u00adpo\u00adrate purposes.Guggenheim Secu\u00adri\u00adties, LLC and Ray\u00admond James & Asso\u00adciates, Inc. served as joint book-run\u00adning man\u00adagers for the offering.A shelf reg\u00adis\u00adtra\u00adtion state\u00adment relat\u00ading to the secu\u00adri\u00adties being sold in this offer\u00ading was filed with the U.S. Secu\u00adri\u00adties and Exchange Com\u00admis\u00adsion (the \u201cSEC\u201d) and was declared effec\u00adtive by the SEC on July 17, 2020. The offer\u00ading was made only by means of a prospec\u00adtus and a prospec\u00adtus sup\u00adple\u00adment. A prospec\u00adtus sup\u00adple\u00adment and accom\u00adpa\u00adny\u00ading prospec\u00adtus related to the offer\u00ading have been filed with the SEC and are avail\u00adable at the SEC\u2019s web\u00adsite located at www.sec.gov. Copies of the prospec\u00adtus sup\u00adple\u00adment and accom\u00adpa\u00adny\u00ading prospec\u00adtus related to the offer\u00ading may be obtained by con\u00adtact\u00ading Guggen\u00adheim Secu\u00adri\u00adties, LLC, Atten\u00adtion: Equity Syn\u00addi\u00adcate Depart\u00adment, 330 Madi\u00adson, 8th<\/sup> Floor, New York, NY 10017, or by tele\u00adphone at (212) 518\u20119544, or by email to GSEquityProspectusDelivery@guggenheimpartners.com.\n

This press release shall not con\u00adsti\u00adtute an offer to sell or a solic\u00adi\u00adta\u00adtion of an offer to buy these secu\u00adri\u00adties, nor shall there be any sale of these secu\u00adri\u00adties in any state or juris\u00addic\u00adtion in which such offer, solic\u00adi\u00adta\u00adtion or sale would be unlaw\u00adful prior to reg\u00adis\u00adtra\u00adtion or qual\u00adi\u00adfi\u00adca\u00adtion under the secu\u00adri\u00adties laws of any such state or jurisdiction.<\/p>\n<\/section>\n

About InflaRx N.V.:<\/strong><\/h5>\n
InflaRx (Nas\u00addaq: IFRX) is a clin\u00adi\u00adcal-stage bio\u00adphar\u00adma\u00adceu\u00adti\u00adcal com\u00adpany focused on apply\u00ading its pro\u00adpri\u00adetary anti-C5a tech\u00adnol\u00adogy to dis\u00adcover and develop first-in-class, potent and spe\u00adcific inhibitors of C5a. Com\u00adple\u00adment C5a is a pow\u00ader\u00adful inflam\u00adma\u00adtory medi\u00ada\u00adtor involved in the pro\u00adgres\u00adsion of a wide vari\u00adety of autoim\u00admune and other inflam\u00adma\u00adtory dis\u00adeases. InflaRx was founded in 2007, and the group has offices and sub\u00adsidiaries in Jena and Munich, Ger\u00admany, as well as Ann Arbor, MI, USA.<\/section>\n
Contacts:<\/strong><\/h5>\n
<\/section>\n
\n
\n
\n
\n

InflaRx N.V.<\/strong><\/p>\n

Jor\u00addan Zwick \u2013 Chief Strat\u00adegy Officer
\nEmail:jordan.zwick[at]inflarx.de<\/a>
\nTel: +1 917\u2212338\u22126523<\/p>\n<\/div>\n

MC Ser\u00advices AG<\/strong><\/div>\n<\/div>\n
\n
\n

Katja Arnold, Lau\u00adrie Doyle, Andreas Jungfer
\nEmail:inflarx[at]mc-services.eu<\/a>
\nEurope: +49 89\u2013210 2280
\nUS: +1\u2013339-832\u20110752<\/p>\n

 <\/p>\n

FORWARD-LOOKING STATEMENTS<\/strong><\/h5>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
This press release con\u00adtains for\u00adward-look\u00ading state\u00adments. All state\u00adments other than state\u00adments of his\u00adtor\u00adi\u00adcal fact are for\u00adward-look\u00ading state\u00adments, which are often indi\u00adcated by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cantic\u00adi\u00adpate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctar\u00adget,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cesti\u00admate,\u201d \u201cpre\u00addict,\u201d \u201cpoten\u00adtial\u201d or \u201ccon\u00adtinue\u201d and sim\u00adi\u00adlar expres\u00adsions. For\u00adward-look\u00ading state\u00adments appear in a num\u00adber of places through\u00adout this release and may include state\u00adments regard\u00ading our inten\u00adtions, beliefs, pro\u00adjec\u00adtions, out\u00adlook, analy\u00adses and cur\u00adrent expec\u00adta\u00adtions con\u00adcern\u00ading, among other things, our ongo\u00ading and planned pre\u00adclin\u00adi\u00adcal devel\u00adop\u00adment and clin\u00adi\u00adcal tri\u00adals; the impact of the COVID-19 pan\u00addemic on the Com\u00adpany; the tim\u00ading and our abil\u00adity to com\u00admence and con\u00adduct clin\u00adi\u00adcal tri\u00adals; poten\u00adtial results from cur\u00adrent or poten\u00adtial future col\u00adlab\u00ado\u00adra\u00adtions; our abil\u00adity to make reg\u00adu\u00adla\u00adtory fil\u00adings, obtain pos\u00adi\u00adtive guid\u00adance from reg\u00adu\u00adla\u00adtors, and obtain and main\u00adtain reg\u00adu\u00adla\u00adtory approvals for our prod\u00aduct can\u00addi\u00addates; our intel\u00adlec\u00adtual prop\u00aderty posi\u00adtion; our abil\u00adity to develop com\u00admer\u00adcial func\u00adtions; expec\u00adta\u00adtions regard\u00ading clin\u00adi\u00adcal trial data; our results of oper\u00ada\u00adtions, cash needs, finan\u00adcial con\u00addi\u00adtion, liq\u00aduid\u00adity, prospects, future trans\u00adac\u00adtions, growth and strate\u00adgies; the indus\u00adtry in which we oper\u00adate; the trends that may affect the indus\u00adtry or us and the risks uncer\u00adtain\u00adties and other fac\u00adtors described under the head\u00ading \u201cRisk Fac\u00adtors\u201d in InflaRx\u2019s peri\u00adodic fil\u00adings with the Secu\u00adri\u00adties and Exchange Com\u00admis\u00adsion. These state\u00adments speak only as of the date of this press release and involve known and unknown risks, uncer\u00adtain\u00adties and other impor\u00adtant fac\u00adtors that may cause our actual results, per\u00adfor\u00admance or achieve\u00adments to be mate\u00adri\u00adally dif\u00adfer\u00adent from any future results, per\u00adfor\u00admance or achieve\u00adments expressed or implied by the for\u00adward-look\u00ading state\u00adments. Given these risks, uncer\u00adtain\u00adties and other fac\u00adtors, you should not place undue reliance on these for\u00adward-look\u00ading state\u00adments, and we assume no oblig\u00ada\u00adtion to update these for\u00adward-look\u00ading state\u00adments, even if new infor\u00adma\u00adtion becomes avail\u00adable in the future, except as required by law.<\/section>\n","protected":false},"excerpt":{"rendered":"

InflaRx N.V. (Nas\u00addaq: IFRX), a clin\u00adi\u00ad\u00adcal-stage bio\u00adphar\u00adma\u00adceu\u00adti\u00adcal com\u00adpany devel\u00adop\u00ading anti-inflam\u00ad\u00adma\u00ad\u00adtory ther\u00ada\u00adpeu\u00adtics by tar\u00adget\u00ading the com\u00adple\u00adment sys\u00adtem, announced today that it has com\u00adpleted its under\u00adwrit\u00adten pub\u00adlic offer\u00ading of 15,000,000 com\u00admon shares at a price of $5.00 per share. For each com\u00admon share pur\u00adchased, an investor received a war\u00adrant to pur\u00adchase a com\u00admon share at an exercise [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":12018,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-12017","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-3"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/12017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=12017"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/12017\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/12018"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=12017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=12017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=12017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}